The Effect of Chinese Medicine Compound in the Treatment of Rheumatoid Arthritis on the Level of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies: A Systematic Review and Meta-Analysis.
The Effect of Chinese Medicine Compound in the Treatment of Rheumatoid Arthritis on the Level of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies: A Systematic Review and Meta-Analysis.
复制标题
中药复方治疗类风湿关节炎对类风湿因子及抗环瓜氨酸肽抗体水平影响的系统评价与荟萃分析
DOI：
10.3389/fphar.2021.686360
复制
发表时间：
2021
影响因子：
5.6
通讯作者：
Huang R
中科院分区：
文献类型：
--
作者：
Tang X;Liu Z;Yang Z;Xu S;Wang M;Chen X;Wen Z;Huang R
目的：评价中药复方是否能降低血清类风湿因子（RF）和抗环瓜氨酸肽抗体（抗CCP）水平的现有证据。研究方法：全面检索PubMed、Embase、科克伦图书馆、中国知网、中国科技期刊数据库和万方数据。然后，我们对所有评估CMC治疗方法的随机对照试验（RCT）进行了系统回顾和荟萃分析。本研究在PROSPERO注册，编号CRD 42020216284。结果：共纳入65项研究，包括6099例患者。荟萃分析结果显示，与常规西药治疗相比，CMC单药或联合西药治疗均能在一定程度上降低血清RF（SMD= −0.85，95%CI −1.04 to −0.67）和抗CCP（SMD= −0.56，95%CI −0.79 to −0.32）水平。在疗效荟萃分析中，更多CMC治疗患者在治疗期后达到疗效标准，其中达到ACR 20的相对风险（RR）为1.20 [1.08，1.33]，ACR 50为1.57 [1.38，1.78]，ACR 70为2.21 [1.72，2.84]。两组患者中医证候疗效比较，差异有统计学意义（RR = 1.22，95%CI 1.19-1.26）。结论：通过本荟萃分析和系统评价，我们发现CMC治疗RA在降低RF和抗CCP水平方面是有效的，并且可能比西药单药治疗具有更好的临床疗效。一些活性成分负责这种功效，值得进一步探索。
Objectives: To evaluate the current evidence whether Chinese medicine compound (CMC) can reduce the serum levels of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP). Methods: We comprehensively searched PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure (CNKI), the Database for Chinese Technical Periodicals (VIP), and Wanfang data. We then performed a systematic review and meta-analysis of all randomized controlled trials (RCTs) assessing the CMC therapy methods. This study is registered with PROSPERO, number CRD42020216284. Results: In total, 65 studies were eligible for inclusion, including 6099 patients. The result of the meta-analysis showed that compared with common Western medicine therapy, CMC monotherapy or combined with Western medicine was able to reduce serum RF (SMD= −0.85, 95%CI −1.04 to −0.67) and anti-CCP (SMD= −0.56, 95%CI −0.79 to −0.32) levels to some extent. In the efficacy meta-analysis, a greater number of CMC-treated patients achieved the efficacy criteria after a period of treatment, where the relative risk (RR) was 1.20 [1.08, 1.33] for achieving ACR20, 1.57 [1.38, 1.78] for ACR50, and 2.21 [1.72, 2.84] for ACR70. At the same time, there was a statistically significant difference in the effective rate of the patient's TCM symptoms (RR = 1.22, 95%CI 1.19–1.26). Conclusions: Through this meta-analysis and systematic review, we found that CMC for the treatment of RA is effective in reducing RF and anti-CCP levels and might have better clinical efficacy than Western medicine monotherapy. Some active components are responsible for this efficacy and worth further exploring.
登录
查看更多内容
影响因子：
4.6
作者：
Burska AN;Hunt L;Boissinot M;Strollo R;Ryan BJ;Vital E;Nissim A;Winyard PG;Emery P;Ponchel F
通讯作者：
Ponchel F
影响因子：
27.4
作者：
Forslind, K;Ahlmén, M;Svensson, B
通讯作者：
Svensson, B
影响因子：
15.9
作者：
Harre, Ulrike;Georgess, Dan;Schett, Georg
通讯作者：
Schett, Georg
枳壳总酚提取物与甲氨蝶呤联合治疗类风湿关节炎的协同增强及保肝作用。
影响因子：
7.2
作者：
He, Dan;Liu, Zhenli;Liu, Yuanyan
通讯作者：
Liu, Yuanyan
影响因子：
1.9
作者：
BEGG, CB;MAZUMDAR, M
通讯作者：
MAZUMDAR, M